Clinical Trials Logo

Relapsing Multiple Sclerosis clinical trials

View clinical trials related to Relapsing Multiple Sclerosis.

Filter by:

NCT ID: NCT06143514 Not yet recruiting - Clinical trials for Relapsing Multiple Sclerosis

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

PROVIDE
Start date: March 15, 2024
Phase:
Study type: Observational

The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).

NCT ID: NCT06104683 Not yet recruiting - Multiple Sclerosis Clinical Trials

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

NCT ID: NCT05877963 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

Study to Evaluate Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab

ENHANCE
Start date: June 13, 2023
Phase: Phase 3
Study type: Interventional

The primary purpose of this phase 3b study is to assess efficacy after transition from a current DMT to ublituximab, as measured by T1 Gadolinium (Gd)-enhancing lesions.

NCT ID: NCT05809986 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

Start date: November 27, 2023
Phase:
Study type: Observational

This non-interventional study will compare the effect of Ofatumumab treatment between patients that began Ofatumumab within the 3 years after Multiple Sclerosis diagnosis and patients that began Ofatumumab with more than 3 years of Multiple Sclerosis diagnosis in a real-world setting in Portugal.

NCT ID: NCT05776888 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

KRONOS
Start date: July 10, 2023
Phase:
Study type: Observational

This non-interventional study aims to observe the effect of early versus late Ofatumumab treatment in RMS patients in a real-world setting in Austria over an observational period of 24 months.

NCT ID: NCT05496894 Withdrawn - Clinical trials for Relapsing Multiple Sclerosis

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

Start date: August 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, single-arm, open-label Phase II study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with different doses in participants with Relapsing Multiple Sclerosis. Participants will be randomly enrolled into three treatment groups: Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 group, Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group, and Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group. The primary outcome measure is the cumulative number of new Gd-enhancing lesions at the end of 48 weeks of Mitoxantrone Hydrochloride Liposome Injection treatment in brain MRI.

NCT ID: NCT05344469 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis

AIOLOS
Start date: May 10, 2022
Phase:
Study type: Observational

This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable Disease-modifying Therapy (DMT) for Relapsing Multiple Sclerosis in Germany. Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to approx. two years of treatment. Additionally, medical history of participants will be collected including disease duration, EDSS, MRI parameters and relapses.

NCT ID: NCT05266469 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

Start date: July 26, 2022
Phase:
Study type: Observational

This is a retrospective and prospective, observational mixed-methods (quantitative and qualitative) cohort study of patients who are treated with either Ofatumumab or Ocrelizumab that will be recruited and followed up for one year to collect their profiles across the Gulf countries.

NCT ID: NCT05232825 Active, not recruiting - Clinical trials for Relapsing Multiple Sclerosis

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Ocarina II
Start date: May 3, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

NCT ID: NCT05199571 Active, not recruiting - Clinical trials for Relapsing Multiple Sclerosis

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

Start date: July 22, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ofatumumab s.c. in adult participants with relapsing multiple sclerosis (RMS) in China.